Valuation dashboard for Lyell Immunopharma, Inc. (LYEL) with P/E N/A, P/B 0.90, EV/EBITDA -1.08 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial,...
Analysis Summary
Lyell Immunopharma, Inc. reported revenue of $36000 in the most recent fiscal year, growing at a 5-year CAGR of -65.9%.
Trailing-twelve-month margins: gross margin -85.4%, operating margin -7113.3%, net margin -9202.9%.
At the current price of $10.78, LYEL has negative trailing earnings (P/E not meaningful) and an ROE of -91.62%. Market capitalisation stands at $264M.
Balance sheet quality for LYEL: current ratio of 5.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.90 |
| EV / EBITDA | -1.08 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.36 |
| vs Current Price | -96.7% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma, Inc. | $264M | 0.90 | -91.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $10.78 |
| Market Cap | $264M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -91.62% |
| Return on Invested Capital | -70.80% |
| Return on Assets | -79.86% |
| Gross Margin | -8537.04% |
| Operating Margin | -711329.63% |
| Net Margin | -920285.19% |
Related companies: ACIU · ALDX · ALLO · AMRN · CABA · EDIT · GNLX
Explore sector: Healthcare · Biotechnology
More sections of LYEL: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks